Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

Ditch the needle? Two novel epinephrine formulations — a dry powder nasal spray and a dissolvable sublingual film — are showing strong results in phase II trials. Both absorbed faster and achieved higher plasma concentrations than traditional autoinjectors like the EpiPen, offering hope for patients who struggle with needle-based treatments for severe allergic reactions.
For patients with severe allergies, the EpiPen has long been the go-to — but its needle has always been a barrier. Two new needle-free epinephrine formulations presented at the ACAAI annual meeting are now showing real promise as alternatives for managing anaphylaxis.
The first, an intranasal dry powder (NS002), outperformed a double dose of EpiPen even in patients with nasal congestion from allergic rhinitis — a condition that mimics the congestion seen during anaphylaxis. It reached key hemodynamic thresholds 2–4x faster than the EpiPen. The second, a dissolvable sublingual film called dibutepinephrine, showed faster absorption and higher peak plasma concentrations than both autoinjectors and intramuscular epinephrine, with consistent, reproducible results across multiple studies.
By the Numbers:
Why it matters: Patients are more likely to carry — and use — treatments that are easy and needle-free. These formulations could meaningfully improve real-world outcomes for anaphylaxis, a condition where every second counts.